Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 25 resultados

e-QuoL: e health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patien... ISTITUTO GIANNINA GASLINI participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the int...
2023-12-13 - 2027-12-31 | Financiado

PanCareSurPass: PanCare studies of the scale up and implementation of the digital Survivorship Passport to improve p... ISTITUTO GIANNINA GASLINI participó en un H2020: H2020-SC1-BHC-2018-2020 Almost 500,000 former childhood cancer patients (CCS) are now living in Europe. Compared to the general population, CCS represent a vulnerab...
2021-01-21 - 2025-02-28 | Financiado

TREL: Twinning in Research and Education to improve survival in Childhood Solid Tumours in Lithuania ISTITUTO GIANNINA GASLINI participó en un H2020: H2020-WIDESPREAD-2018-2020 Vilnius University Hospital Santaros Klinikos (VULSK) acts as a coordinator of the TREL (Twinning in Research and Education to improve survi...
2020-06-12 - 2023-12-31 | Financiado

PanCareFollowUp: PanCareFollowUp Novel patient centred survivorship care to improve care quality effectiveness co... ISTITUTO GIANNINA GASLINI participó en un H2020: H2020-SC1-BHC-2018-2020 The 5-year survival for children with cancer increased from 30% in the 1970s to more than 80% at present. There are up to 300,000 childhood...
2018-12-10 - 2023-12-31 | Financiado

c4c: conect4children COllaborative Network for European Clinical Trials For Children ISTITUTO GIANNINA GASLINI participó en un H2020: H2020-JTI-IMI2-2016-10-two-stage Paediatric medicines development is embedded in the European policy, legislation and in the work of the pharmaceutical industry but currentl...
2018-06-22 - 2025-04-30 | Financiado

TAT-CF: Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembr... ISTITUTO GIANNINA GASLINI participó en un H2020: H2020-PHC-2014-2015 This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the d...
2015-12-01 - 2018-12-31 | Financiado

ABIRISK: Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the ri... ISTITUTO GIANNINA GASLINI participó en un FP6: The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
2012-03-01 - 2018-02-28 | Financiado

Health-e-Child: Health-e-Child ISTITUTO GIANNINA GASLINI participó en un FP6: There is a compelling demand for the integration and exploitation of heterogeneous biomedical information for improved clinical practice, me...
2006-01-01 - 2010-04-30 | Financiado

INNATE_CROSSTALK: Innate immunity crosstalk in immunoregulation ISTITUTO GIANNINA GASLINI tramitó un FP7: Innate immunity is believed to protect mammalians from most infections. In the majority of cases, the quick responses by innate effector cel...
Financiado

ABIRISK: Anti Biopharmaceutical Immunization Prediction and analysis of clinical relevance to minimize the ri... ISTITUTO GIANNINA GASLINI participó en un FP7: The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique pane...
Financiado

ENCCA: EUROPEAN NETWORK for CANCER research in CHILDREN and ADOLESCENTS ISTITUTO GIANNINA GASLINI participó en un FP7: ENCCA aims to establish a durable, European Virtual Institute clinical and translational research in childhood and adolescent cancers that w...
Financiado

PANCARESURFUP: PanCare Childhood and Adolescent Cancer Survivor Care and Follow up Studies ISTITUTO GIANNINA GASLINI participó en un FP7: Over the last 40 years, treatment for childhood and adolescent cancer has improved greatly; 5- year survival after childhood cancer is now 8...
Financiado

INFLA-CARE: Understanding inflammation associated tumorigenesis for the rational design of novel anti cancer the... ISTITUTO GIANNINA GASLINI participó en un FP7: Epidemiological and experimental evidence supports a link between chronic inflammation and cancer and indicates a role for inflammatory cell...
Financiado

LEUKOTREAT: Therapeutic challenge in Leukodystrophies Translational and ethical research towards clinical trial... ISTITUTO GIANNINA GASLINI participó en un FP7: Leukodystrophies (LDs) are inherited rare neurodegenerative diseases of the white matter and its main component, the myelin, that are affect...
Financiado

EPIPGX: Epilepsy Pharmacogenomics delivering biomarkers for clinical use ISTITUTO GIANNINA GASLINI participó en un FP7: The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and s...
Financiado

DESIRE: Development and Epilepsy Strategies for Innovative Research to improve diagnosis prevention and t... ISTITUTO GIANNINA GASLINI participó en un FP7: DESIRE will focus on epileptogenic developmental disorders EDD, i.e. early onset epilepsies whose origin is closely related to developmental...
Financiado

MD PAEDIGREE: Model Driven European Paediatric Digital Repository ISTITUTO GIANNINA GASLINI participó en un FP7: MD-Paedigree is a clinically-led VPH project that addresses both the first and the second actions of part B of Objective ICT-2011.5.2:1. it...
Financiado

GAPP: GAbapentin in Paediatric Pain ISTITUTO GIANNINA GASLINI participó en un FP7: Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate...
Financiado

PHARMACHILD: Long term PHARMacovigilance for Adverse effects in Childhood arthritis focussing on Immune modulator... ISTITUTO GIANNINA GASLINI participó en un FP7: Until the age of biotechnology, treatment options for children and adolescents with severe arthritis, inflammatory bowel diseases and other...
Financiado

CUREHLH: European initiative to improve knowledge treatment and survival of haemophagocytic syndromes in chi... ISTITUTO GIANNINA GASLINI participó en un FP7: Haemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening inherited immune disorder of early childhood characterised by an un...
Financiado